Introduction

The World Health Organization (WHO) notified 2.1% global case fatality rate for COVID-19 with significant geographical variation (13 July 2021). Pregnancy is associated with cardio-pulmonary and immunological changes predisposing women to severe respiratory illnesses as was seen in epidemics of two beta coronaviruses, Severe acute respiratory syndrome (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV) with maternal mortality of 15% and 27% respectively. Literature regarding novel COVID-19 virus impact on pregnant women is varied - initial reports suggesting comparatively a benign course in pregnancy with zero mortality; recent sporadic case reports and series along with surveillance databases warning about the potential risks associated with maternal deaths occurring in postpartum period. Late referral, loss to follow-up and inadequate care were important determinants of maternal mortality. We concluded that pregnancy cases with or without complications must be considered high risk and addressed judiciously beginning from infection prevention, early diagnosis, disease categorization, and multidisciplinary approach of management to prevent morbidity and mortality. We strongly suggest strengthening the health care delivery system to save pregnant women from dying, particularly in low-resource countries.

Keywords: ARDS, COVID-19, cytokine storm, DIC, maternal deaths, maternal mortality, septic shock, venous thromboembolism
COVID-19 in pregnancy.\textsuperscript{[3]} We reviewed our institutional data from 1 April to 31 December 2020, where a total of 140 RTPCR confirmed antenatal cases got admitted. There were three maternal mortalities. Institutional COVID-19 related maternal case fatality rate was 2.14\% (3/140); in nonpregnant women it was 3.39\% (44/1295) and in the overall infected population it was 4.02\% (136/3375). The maternal mortalities are often under-reported with lack of mention of exact factors responsible for them. Metz et al.\textsuperscript{[4]} highlighted the importance of maternal mortality review committee to investigate maternal deaths due to COVID-19. So, the present study was undertaken to probe into the factors responsible for maternal mortalities due to COVID-19 along with the description of our institutional experience of the same. This would enhance the available data and predict determinants of maternal mortality due to COVID-19.

Methods

We did a comprehensive review of the literature with reference to our institutional experience to understand maternal deaths due to COVID-19 in detail (GIMS/IEC/HR/2020/13). The search was conducted in the PubMed, Embase, and Google Scholar databases, using the keywords “maternal mortality”, “maternal death”, “COVID-19”, “septic shock” and “DIC”. The search included original articles, review articles, case reports published till date in English that included maternal mortality due to COVID-19 in the antepartum period or until 6 weeks after delivery. Total 83 studies were screened. Studies with data duplication, unreported and incomplete data reporting, and preprint studies were excluded. Total 42 studies were included in this narrative review.

Experience of our tertiary care center of 3 maternal deaths

Case 1, Mrs. X, a 25-year-old pregnant woman, known asthmatic, unbooked primigravida, with 26 weeks gestation, got admitted with a positive RT PCR report for SARS CoV-2. She has complaint of fever and cough for 4 days and shortness of breath (SOB) for 2 days. She was dyspneic with respiratory rate 38/min, SpO2 (oxygen saturation) 82\% on room air, pulse rate 134/min, blood pressure 116/76 mmHg with Quick Sequential Organ Failure Assessment (q-SOFA) score of 1 on admission. Obstetrical examination revealed a relaxed uterus of 26 weeks fundal height. Patient was admitted in COVID intensive care unit (ICU) and oxygen supplementation was given via non-rebreathing mask with the reservoir at 12 liters/min raising saturation to 98\%. Bronchodilators- both systemic and inhalational injectable steroids, 3\textsuperscript{rd} generation antibiotics, and leukotriene inhibitors were started. All relevant investigations were done. X-ray revealed patchy alveolar opacities in the bilateral mid and lower lung zones suggesting viral pneumonia. d-dimer and lactate dehydrogenase (LDH) were markedly raised. Low molecular weight heparin (LMWH) 40 mg subcutaneously and aspirin 75 mg orally daily were initiated. Repeat X-ray on day 3 of admission showed bilateral confluent opacities suggesting acute respiratory distress syndrome (ARDS). In view of persistent dyspnea and rising leukocyte count, antibiotics were stepped up and the option of convalescent plasma therapy was given which was transfused on days 4 and 5 of admission. Exogenous oxygen support continued until day 6 when she acutely decompensated, intubated, and kept on ventilatory support but expired after a total stay of 5 days 6 h. Probable cause of death was acute respiratory failure secondary to COVID-19 pneumonia with ARDS with bronchial asthma at 26 weeks gestation.

Case 2, Mrs Y, a 32-year-old elderly primigravida, in-vitro fertilization (IVF) conceived, a diamniotic dichorionic twin gestation of 36 weeks 4 days period of gestation, with COVID-19 positive RTPCR reported with a complaint of leaking per vaginum for 6 h. She was asymptomatic with no history of contact or travel and was lost to follow up for the last 2 months due to lockdown. She was an average-built woman having pulse rate 102/min, blood pressure 126/92 mm Hg, respiratory rate 22/min, and SpO2 97\% on room air with presence of pallor, icterus, and pedal edema. Abdomen was overdistended with the first fetus in breech presentation. On internal examination, leaking was present and liquor was meconium tinged, the internal os was closed, and the calculated Bishop’s score was 3. Cardiotocography showed late deceleration in the first twin. She underwent an emergency caesarean section under regional anesthesia delivering two male babies of 2.4 kg and 2.2 kg with two separate placentas. Patient had atomic postpartum hemorrhage (PPH) at the operation table which was managed timely by the uterotonic agents; carboprost, oxytocin, and tranexamic acid. She was shifted to the COVID-ICU. Her investigations, collected postoperatively, showed deranged liver and kidney functions; leukocytosis; raised CRP (C-Reactive protein), LDH, and d-dimer suggestive of probable COVID related dysfunction while pre-eclampsia with HELLP syndrome was also considered in the differential diagnosis (although there was no proteinuria and blood pressure was never ≥140/90 mm Hg). Chest X-ray was normal. In view of sepsis with organ dysfunction, she was switched to fourth generation antibiotics, vitamin K and injection frusemide 20 mg 8 hourly. Being postoperative case with atomic PPH during surgery, it was planned to initiate LMWH 24 h post-operatively. She remained stable until 18 h post-operatively when she suddenly complained dyspnea and perspiration; SpO2 dropped to 48\% , blood pressure 80/50 mm Hg and pulse rate 132/min suggesting acute hemodynamic instability. She was immediately intubated and noradrenaline infusion started. Sonography revealed rectus sheath hematoma. She was reexplored, the rectus sheath hematoma was drained removing 800cc of blood clots. Two units of blood and four fresh frozen plasma were transfused with continuation of ionotropic support. Her vitals were maintained while urine output started decreasing. On day 2, she again went into shock with SpO2 falling to 70\%, ionotropic support was escalated, cardiopulmonary resuscitation was done but despite the measures taken, she expired on postpartum day 2 after 1 day and 17 h of stay. The probable cause of death was thromboembolism with multiple organ dysfunction syndrome (MODS) with sepsis secondary to COVID-19.
Case 3, Mrs. Z, a 30-year-old gravida 2 with previous caesarean delivery with 34 weeks 5 days gestation with hypothyroidism and preeclampsia got admitted with complaints of fever for 5 days and shortness of breath for 2 days. She had been admitted at a private hospital for the last 5 days with complaints of fever, headache, and gastrointestinal symptoms. She was diagnosed as a case of lower respiratory tract infection with preeclampsia and was managed for the same. Later, she was referred to the higher center in view of persistent fever with shortness of breath having strong clinical suspicion of COVID-19. At the time of referral, her SPO2 was 94% at ambient air, respiratory rate 22/min, blood pressure 140/70 mmHg, and pulse 98/min. Before coming to our institute, she visited various hospitals where admission was denied owing to either unavailability of beds or the facility not being a dedicated COVID-19 center. When she came to our institute, she was gasping with altered sensorium, SpO2 40%, pulse feeble, blood pressure not recordable. She was immediately intubated and put on mechanical ventilation with 100% FiO2 and ionotropic support started. Cardiopulmonary resuscitation initiated. Despite maximum resuscitative efforts, she expired within half an hour of her arrival with a probable diagnosis of COVID-19 suspect with ARDS with severe hypoxemic shock. Later, her RTPCR came out to be positive for SARS-CoV2. We don't have any other investigations available to us. However, we discussed this case to highlight the importance of clinical diagnosis and a robust referral health system to manage such cases. Clinical outcomes, biochemical and radiological parameters of the first two cases have been compiled in Tables 1 and 2.

Prognostic factors in relation to critical disease in pregnancy

Review of the literature regarding fatality and prognostic factors revealed that the commonest fatal complications in COVID-19 infection include acute hypoxic respiratory failure, venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), cytokine storm, septic shock, acute liver, kidney, and cardiac injury.[5,6]

**Acute respiratory failure**

Acute respiratory failure is the leading cause of mortality in COVID-19, especially in comorbid conditions like chronic obstructive pulmonary disease, advanced age, obesity, smoking, etc.[7] Case 1 was a known asthmatic with COVID pneumonia with severe unresponsive hypoxia.

**Cytokine storm**

Cytokine storm in COVID-19 may cause ARDS or MODS and even death.[8] Elevated proinflammatory cytokines (interleukin-2, 6, 8, 10, tumor necrosis factor-alpha) and inflammatory markers (C-reactive protein (CRP), serum ferritin, LDH, d-dimer, Procalcitonin) have been reported.[9] A case reported from US highlighted about cytokine storm, elevated d-dimer (24 fold higher), and MODS resulting in maternal death post caesarean after 36 h of admission.[10] The findings of this case could be readily correlated to case 2 with elevated D-dimer, CRP, and LDH rapidly progressing to MODS post caesarean and resulting in death after 41 h of admission. Case 1 with elevated D-dimer (four times) and LDH progressed to ARDS.

**Thrombo-embolism**

Thrombo-embolism has been reported in 20-80% of severe COVID-19 cases and is attributed to cytokine storm, hypoxic injury, endothelial dysfunction, hypercoagulability, etc. Risks are widened in pregnancy due to hypercoagulability, multiple gestations and post caesarean immobility.[11-18] In COVID-19, the local inflammatory process in the lung itself, rather than dislodged emboli, is responsible for the formation of pulmonary micro-thrombi.[14] Elevated D-dimer levels are directly related to the risk of VTE. Case 2, having no documented co-morbidity, underwent emergency caesarean; further, she was an elderly

| Parameters                  | Case 1                                  | Case 2                                           |
|-----------------------------|-----------------------------------------|-------------------------------------------------|
| Age                         | 25 yr                                   | 32 yr                                           |
| Parity                      | G1P0                                    | G1P0                                            |
| Gestation                   | singleton gestations at 26 weeks         | Diamniotic Dichorionic IVF conceived twin gestation at 36 weeks 4 days                        |
| Symptoms                    | Shortness of breath, fever              | Asymptomatic                                    |
| q-SOFA score on admission   | 1                                       | 0                                               |
| Co morbidities              | Bronchial Asthma                         | None                                            |
| Poor prognostic factors     | Raised TLC, Lymphopenia, Neutrophilia    | Raised TLC, CRP, Neutrophilia, Raised            |
|                             | Raised D Dimer and LDH                   | D-Dimer and LDH, Deranged LFT & KFT, Hypoproteinemia |
| Delivered                   | No                                      | Yes - Caesarean Section                         |
| Operated                    | No                                      | Yes (twice- caesarean and laparotomy)           |
| O2 support                  | Yes                                     | No                                              |
| Ventilator support          | Yes, antepartum on Day 6                | Yes, post-partum day 1                          |
| Low molecular weight heparin| Yes                                     | No                                              |
| Plasma therapy              | Yes                                     | No                                              |
| Probable cause of death     | Acute respiratory failure secondary to   | Venous thromboembolism with Multi organ dysfunction syndrome and Sepsis                     |
|                             | COVID pneumonia with ARDS                |                                                 |
| Hospital stay               | 5 days 6 h                               | 1 day 17 h                                      |
primigravida with twin gestation, had elevated D-dimers, CRP, and LDH levels – all increasing risk of VTE. Demelo-Rodríguez and Wichmann reaffirmed it by reporting high incidence of asymptomatic venous thrombosis in COVID-19 cases (14.7% and 58% respectively)\(^\text{[15,16]}\). Ahmed et al.\(^\text{[17]}\) reports the first maternal death in the UK due to venous thromboembolism and basilar artery thrombosis.

**Disseminated intravascular coagulation (DIC)**

DIC related to severity is reported in 71% of non-survivors and manifests clinically with bleeding and biochemically as elevated fibrinogen, high D-dimer with minimal change in prothrombin time, activated partial thromboplastin time and platelet count.\(^\text{[18]}\) Similar findings were observed in case-2 with abdominal wall bleeding. LMWH prophylaxis is recommended against VTE and DIC till 36 weeks and in the postpartum period while unfractionated heparin after 36 weeks because of short half-life.\(^\text{[19]}\) We could not start LMWH in Case-2 as she was an immediate post caesarean case with per operative atomic PPH followed by rectus sheath hematoma.

**Acute Liver and Kidney injury**

Acute Liver and kidney injuries can occur due to cytokine storm or micro-thrombi mediated damage and are directly related to the severity of infection. Deranged Liver enzymes, elevated bilirubin, and reduced albumin are reported in one-third patients,\(^\text{[20,21]}\) and acute kidney injury in 5-10% of patients.\(^\text{[22]}\) In Case-2, both liver and renal functions were grossly deranged with hypoalbuminemia, which may explain the rapid progression to the critical stage.

**Septic shock**

Septic shock has been reported in 4% to 8% of COVID-19 patients with noradrenaline being the preferred first-line agent for management.\(^\text{[23]}\) Case-2 developed septic shock after caesarean section and progressed to MODS.

**Presence of comorbidities**

Takemoto et al.\(^\text{[24]}\) reported 20 COVID-19 related maternal deaths in Brazil. Among 20, 9 women had ≥ 1 comorbidities and 5 out of 9 were asthmatic. Case-1 was also known asthmatic.

### Table 2: Biochemical and radiological profile of two cases

| Investigations with reference values | Day 1 | Day 6 | Day 1 | Day 2 |
|-------------------------------------|-------|-------|-------|-------|
| Hemoglobin (11.5-15 gm/dl)           | 11.3  | 10.7  | 13.2  | 10    |
| Total Leucocyte Count (4000-10,000 cell/mm³) | 12300 | 15300 | 20200 | 22000 |
| Hemoglobin (11.5-15 gm/dl)           | 11.3  | 10.7  | 13.2  | 10    |
| Total Leucocyte Count (4000-10,000 cell/mm³) | 12300 | 15300 | 20200 | 22000 |
| Polymorphs (P 40-80%)              | 82    | 85    | 71    | 84    |
| Lymphocytes (L 20-40%)             | 11    | 9     | 20    | 18    |
| Eosinophils (E 1-6%)               | 5     | 4     | 7     | 6     |
| Monocytes (M 2-10%)                | 2     | 2     | 2     | 2     |
| Platelet (1.5-4 lac/mm³)           | 2.77  | 3.28  | 1.4L  | 1.4L  |
| Blood Sugar (70-140 mg/dl)         | 109.6 | -     | 90    | 49.4  |
| Urea (13-43 mg/dl)                 | 16.0  | 24.7  | 74    | 80    |
| Creatinine (0.6-1.2 mg/dl)         | 0.77  | 0.7   | 3.08  | 3.5   |
| Uric acid (2.6-6.0 mg/dl)          | 4.6   | 2.3   | 9.6   | 9     |
| Bilirubin Total (0.3-1.2 mg/dl)    | 0.6   | 0.65  | 9.7   | 9.5   |
| Direct <0.2 mg/dl                  | 6.8   | 6.7   | 6.7   | 6.7   |
| Indirect (0.2-0.7 mg/dl)           | 2.94  | 2.8   | 2.8   | 2.8   |
| Aspartate aminotransferase <40 IU/L | 76    | 144   | 250   | 258   |
| Alanine aminotransferase <40 IU/L  | 62    | 133.5 | 201   | 220   |
| Alkaline phosphatase (60-240 IU/L) | 241.7 | 243.5 | 900   | 978   |
| Proteins (3.8-5.5 mg/dl)           | 4     | 4.1   | 3.3   | 3.2   |
| Prothrombin Time                   | 14.9  | 14.2  | 14.8  | 15.3  |
| Activated Partial Thromboplastin time (28.69-41.89) | 32.5 | 31.2 | 39.3 | 42.5 |
| International normalized ratio INR | 1.10  | 1.05  | 1.09  | 1.13  |
| D-Dimer <500 mg/ml                 | 2847  | 3500  | 10,000 | >10,000 |
| CRP <3 mg/L                        | 1     | 2     | 37.6  | 40    |
| Lactate Dehydrogenase LDH (125-220 U/L) | 772  | 792   | 597   | 655   |
| Ferritin (15-150 mg/ml)            | 72.8  | 65    | 66.54 | 74    |
| Arterial blood gas analysis (ABG)  | Mild respiratory alkalosis | Severe metabolic acidosis | Not done | Severe metabolic acidosis with hypoxia with hyperkalemia |

**Chest X ray**

| Patchy alveolar opacities bilateral mid and lower lung zones ? viral pneumonia | Day 4 Patchy confluent opacities bilateral lungs ?ARDS | Apparently normal | RALE score: 30 |
|-----------------------------------------------------------------------------|--------------------------------------------------------|------------------|---------------|
| RALE Score: 42                                                             | RALE Score: 0                                           |                  |               |

**References**

\(^{[15,16]}\) Ahmed et al.;\(^{[17]}\) Takemoto et al.;\(^{[20,21]}\) Case-2 developed septic shock after caesarean section and progressed to MODS.
Given the similarity between the climate and geography of India and Brazil, this finding has important implications. Pregnant women with COPD, asthma, and other respiratory ailments should be given priority-based care. Other studies also reported presence of the comorbidities: obesity, diabetes, asthma, hypothyroidism, and advanced maternal age among maternal deaths.[25,26] On the contrary, out of the 7 maternal deaths reported by Hantoushzadeh et al.,[27] 5 had no underlying health issues suggesting that pregnancy itself could put women at higher risk of more severe consequences from SARS-CoV-2 infection.

**Gaps in maternity care**

Case 2 was lost to follow-up while case 3 was a victim of poor referral system similar to a case of maternal mortality reported by Zamanian et al.[27] Kumari et al.[28] reported 43.2% reduced hospital admissions, 66.4% reduction in referred obstetric emergencies and observed a significant increase in maternal mortality (0.20 vs 0.13%; P = 0.01) due to lockdown. Establishment of social distancing norms and COVID-related psychological stress could have possibly led to avoidance of hospitals by pregnant women. A study from Brazil has also attributed inadequate health care access and presence of risk factors to maternal mortality in COVID-19.[29] This highlights the gap between expected and tendered quality of maternity health services received by pregnant women even after the introduction of “Point-of-care Quality Improvement” by WHO.[30]

**Burden of Disease and Case fatality rate**

As far as the burden of COVID-19-related maternal morbidity and mortality is concerned, Centres for Disease Control and Prevention on 12 July 2021 reported 113 maternal deaths out of 100,472 cases, 13.7% ICU admissions with 9.4% receiving invasive ventilation.[30] An earlier report by CDC stated that symptomatic pregnant women were at significantly increased risk for severe outcomes compared with nonpregnant women. After adjusting for all contributing factors, CDC reports that compared to nonpregnant women, pregnant women had more ICU admissions (3.9 vs 10.5 per 1000 cases), more cases receiving invasive ventilation (1.1 versus 2.9 per 1000 cases), and more case fatality rate (1.2 per 1,000 cases vs 1.5 per 1,000 cases) suggesting 70% increased relative risk for mortality in them. CDC also reports more afflictions by COVID-19 in Hispanic black and Asian women compared to non-Hispanic white women, suggesting racial and ethnic disparities. In the subgroup analysis, it was found that pregnant women of age group 35–44 years with COVID-19 had four times more risk of invasive ventilation and two times more risk of dying than nonpregnant women of the same age.[31] Lumbreras-Marquez et al.[32] reported the difference between anticipated and actual maternal mortality ratio (29.5 vs 42.4, respectively) in Mexico till August 2020, with 32% higher deaths owing to respiratory ailments. COVID-19 is among the leading causes for the same.

Various studies have reported varying case fatality rates (CFR) of 0.1% to 12.9% for pregnant women infected with COVID-19.[6,24,25,30,41] In the largest living systematic review and meta-analysis till date, Allocy et al.[33] highlighted some key findings: 10% pregnant women attending the hospital for any reason is diagnosed with suspected/confirmed COVID-19, the pregnant women are less likely to be symptomatic and are more prone for ICU admission and invasive ventilation with case fatality rate of 1%. Juan J et al.[34] in a review including 324 pregnant patients with COVID-19 infection reported the rate of severe pneumonia from 0–14% and there were 9 (2.7%) maternal deaths. Institutional maternal CFR (case fatality rate) for COVID-19 at our institute was 2.14%.

**Time Frame of the Event (Maternal Mortality)**

In a systematic review by Hessami et al.[35] they reported that out of the total 37 maternal deaths, 31 of the deaths occurred in the postpartum period. High mortality in postpartum period is also supported by other studies emphasizing the need to optimize postpartum care.[6,24,39]

Case 2 died in the postpartum period. However, Toro et al.[36] in a systematic review and meta-analysis concluded that there is significantly more disease progression in antenatal women as compared to post-natal women.

**Role of Primary Care Physicians**

Primary care physicians are the physicians of first contact forming the crucial link in the referral chain. Timely decisions and interventions by them could generate a significant difference in the maternal outcome. This study will help them in identifying the Covid-19 pregnant women with high-risk factors. This article will sensitise them towards rampant issue of maternal mortality and help them in timely referral to a designated tertiary COVID-19 hospital which was not done in case 3. Being the physicians of first contact with the knowledge of increased severity of Covid-19 in pregnant patients, they could also motivate pregnant and lactating mother to voluntarily opt for COVID-19 vaccination as per Government of India guidelines.[42]

**Key Learning Points**

- Prognostic factors associated with Covid-19 pregnancy cases include the presence of COVID-19 symptoms, increased age, comorbidities, lymphopenia, elevated D-dimer, elevated inflammatory markers, liver, kidney, and cardiac injury markers, cesarean delivery, and gaps in maternity care.
- Patients without symptoms and having normal imaging should not be taken lightly, instead the full biochemical profile should be done and used for disease categorization. It is difficult to ascertain the actual contribution of COVID-19 to maternal mortality at times because changes in biochemical parameters may mimic pregnancy-associated complications.
- As routine follow-up of patients is reduced in the pandemic, pregnancy-related complications are often missed and
Table 3: COVID-19 related maternal morbidity and mortality among various studies

| Authors                          | Study type                                      | Total no. of COVID-19 Pregnant women | Percentage of pregnant patients with severe/critical COVID-19 | Total no. of maternal COVID-19 deaths; Case fatality rate | Comments                                                                                                                                                                                                 |
|---------------------------------|------------------------------------------------|--------------------------------------|-------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Papapanou et al. (Jan 2021)     | Systematic review and meta-analysis            | -                                    | 3-10%                                                       | <2%                                                      | This study attributed contradictory maternal rates across the world to differing healthcare infrastructure in various countries.                                                                          |
| Chi et al. (Dec 2020)           | Systematic review and meta-analysis            | 230                                  | 17.5%                                                       | 1; 0.43%                                                 | 15 out of 20 studies included in this review were from China. So, the findings of this study can't be generalised.                                                                                     |
| Kim et al. (Nov 2020)           | Systematic review and meta-analysis            | 85 (all ICU cases)                   | 100%                                                        | 11; 12.9%                                                | 1. The unusually high case fatality rate is because of including only patients admitted to ICU.                                                                                                       |
|                                |                                                |                                      |                                                             |                                                          | 2. This study emphasizes the importance of recognizing maternal disease severity and associated intervention timely to decrease the risk of death in critically ill pregnant patients.                         |
| Taro et al. (Nov 2020)         | Systematic review and meta-analysis            | 1100                                 | 8%                                                          | 5; 0.45%                                                 | This study demonstrated case fatality rate in pregnant and non-pregnant females to be the same. However, the studies included exhibited significant heterogeneities.                                             |
| Allotey et al. (Sept 2020)      | Living Systematic review and meta-analysis     | 11,432                               | 13%                                                         | 73; 0.1%                                                 | They observed increased incidence of asymptomatic disease, ICU admission and invasive ventilation in pregnant patients as compared to non-pregnant women.                                                  |
| Khalil et al. (July 2020)       | Systematic review and meta-analysis            | 2567                                 | 7%                                                          | 43; 0.9%                                                 | Only studies with sample size >15 included. Small case series/case reports were excluded.                                                                                                                                                                      |
| Di Masicio et al. (Sep 2020)    | Multinational retrospective cohort study from WAPM* | 388                                  | 11%                                                         | 3; 0.8%                                                  | 1. There was no statistically significant difference in the maternal mortality and morbidity observed between different regions.                                                                        |
|                                |                                                |                                      |                                                             |                                                          | 2. The presence of COVID-19 symptoms was only predictor of primary outcome (composite measure of maternal mortality and morbidity).                                                                  |
|                                |                                                |                                      |                                                             |                                                          | 3. Non-inclusion of low-income countries limits the generalization of findings.                                                                                                                                                                          |
| Marquez et al. (Aug2020)        | Research Article                               | 308                                  | -                                                           | 7; 2.3%                                                  | 1. They highlighted the gap between expected and delivered level of maternity care.                                                                                                                   |
| (Mexico)                        |                                                |                                      |                                                             |                                                          | 2. The role of COVID-19 as a direct or indirect cause of mortality was not clear.                                                                                                                  |
| Takemoto et al. (Aug2020)       | Research Article                               | 978 (all ARDS cases)                 | 100%                                                        | 124; 12.4%                                               | 1. The disturbing high case fatality rate is due to inclusion of only COVID-19 pregnant women with ARDS.                                                                                              |
| (Brazilian ARDS surveillance system) |                                              |                                      |                                                             |                                                          | 2. Authors have missed the opportunity to compare this result to the non-pregnant women affected with COVID-19 induced ARDS.                                                                        |
|                                |                                                |                                      |                                                             |                                                          | 3. This case fatality rate may not be true as 30% cases were not included due to incomplete data.                                                                                                   |
| Hantoushzadkh et al. (July 2020) | Case Series                                    | 9                                    | 100%                                                        | 7; 77%                                                   | Mortality rate for severe cases cannot be generalized from this study as it is not a surveillance cohort. However, it is one of the first case series to show that maternal mortality due to COVID-19 is not zero. |
| Antoun et al. July 2020 (UK)    | Prospective cohort study                       | 23                                   | 34.8%                                                       | 1; 4.3%                                                  | This study presents data from early phase of the pandemic from UK with 70% of the infected patients from Asian background.                                                                         |

* (World Association of Perinatal Medicine) working group

Treatment is delayed. Therefore, there is an urgent need to introduce telemedicine facilities and strengthen the health referral systems in developing countries. Comprehensive review of all maternal deaths should be done critically so that steps to reduce these tragic events in the future can be taken.
Strengths and Limitations

Strengths
- This is a comprehensive narrative review of maternal mortality complemented by data from our institute.
- All possible direct and indirect COVID-19 related maternal mortality have been discussed with supportive evidence from the literature.

Limitations
- Quality of the studies was not assessed.
- Under-reporting of maternal deaths by various countries might have led to underestimation of the issues (determinants of maternal mortality) discussed.

Conclusions

The potential risk of maternal mortality in COVID-19 pregnancies cannot be underestimated. Although the number of maternal mortality appears small, obstetricians need to be well versed with the factors predictive of poor outcome. Decoding maternal mortality and strengthening the health care delivery systems is vital to save pregnant women from dying, particularly in low-resource countries.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int. [Last accessed on 2021 Jul 14].
2. Mullins E, Evans D, Viner RM, O’Brien P, Morris E. Coronavirus in pregnancy and delivery: Rapid review. Ultrasound Obstet Gynecol 2020;55:586-92.
3. Sharma R, Seth S, Sharma R, Yadav S, Mishra P, Mukhopadhyay S. Perinatal outcome and possible vertical transmission of coronavirus disease 2019: Experience from North India. J Korean Pediatr Soc (accepted) 2022;64:239-46.
4. Metz TD, Collier C, Hollier LM. Maternal mortality from coronavirus disease 2019 (COVID-19) in the United States. Obstet Gynecol 2020;136:313-6.
5. Coronavirus disease 2019 (COVID-19)-Symptoms, diagnosis and treatment [BMJ Best Practice. Available from: https://bestpractice.bmj.com/topics/en-gb/3000201. [Lat accessed 2021 Jan 4].
6. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal death due to COVID-19. Am J Obstet Gynecol 2020;223:109.e1-109.e16.
7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-8.
8. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80:607-13.
9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
10. Vallejo V, Ilagan JG. A postpartum death due to coronavirus disease 2019 (COVID-19) in the United States. Obstet Gynecol 2020;136:52-5.
11. Llitjos JF, Leclerc M, Chocois C, Monsallier JM, Ramakers M, Aufray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743-6.
12. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation 2020;142:184-6.
13. Martínez-Perez O, Vouga M, Cruz Melguizo S, Forcen Acebal L, Panchaud A, Muñoz-Chápuli M, et al. Association between mode of delivery among pregnant women with COVID-19 and maternal and neonatal outcomes in Spain. JAMA 2020;324:296-9.
14. McGonagle D, O’Donnell JS, Shairk F, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020;2:e437-45.
15. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macias M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020;192:23-6.
16. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Doerschug K, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann Intern Med 2020;173:293-8.
17. Ahmed I, Azhar A, Eltaweel N, Tan BK. First COVID-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol 2020;190:37-8.
18. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-7.
19. Moores LK, Trittshler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest 2020;158:1143-63.
20. Kunutsor SK, Laukkanen JA. Hepatic manifestations and complications of COVID-19: A systematic review and meta-analysis. J Infect 2020;81:e72-4.
21. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J 2020;8:509-19.
22. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients. Pharmacol Res 2020;161:105107. doi: 10.1016/j.phrs.2020.105107.
23. Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S, et al. Sepsis and coronavirus disease 2019: Common features and anti-inflammatory therapeutic approaches. Crit Care Med 2020;48:1841-4.
24. Takehito MLS, Menezes MO, Andreucci CB, Knobel R, Sousa LR, Katz L, et al. Maternal mortality and COVID-19. J Matern Fetal Neonatal Med 2020;1–7. doi: 10.1080/14767058.2020.1786056.
25. Lumberas-Marquez MI, Campos-Zamora M, Lizaola-Diaz-de Leon H, Farber MK. Maternal mortality from...
COVID-19 in Mexico. Int J Gynaecol Obstet 2020;150:266-7.

26. Hessami K, Homayoon N, Hashemi A, Vafaei H, Kasraeian M, Asadi N. COVID-19 and maternal, fetal and neonatal mortality: A systematic review. J Matern Fetal Neonatal Med 2020;1-6. doi: 10.1080/14767058.2020.1806817.

27. Zamanian M, Ebadi A, Aghajanpoor S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection. Prenat Diagn 2020;40:1759-61.

28. Kumari V, Mehta K, Choudhary R. COVID-19 outbreak and decreased hospitalisation of pregnant women in labour. Lancet Glob Health 2020;8:e1116-7.

29. Point Of Care Quality Improvement. Available from: https://www.pocqi.org/india/. [Last accessed on 2021 Jan 4].

30. CDC. COVID Data Tracker. Centers for Disease Control and Prevention. 2020. Available from: https://covid.cdc.gov/covid-data-tracker. [Last accessed on 2021 Jul 15].

31. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1641-7.

32. Papapanou M, Papaioannou M, Petta A, Routsi E, Farmaki M, Vlahos N, et al. Maternal and neonatal characteristics and outcomes of COVID-19 in pregnancy: An overview of systematic reviews. Int J Environ Res Public Health 2021;18:596.

33. Chi J, Gong W, Gao Q. Clinical characteristics and outcomes of pregnant women with COVID-19 and the risk of vertical transmission: A systematic review. Arch Gynecol Obstet 2021;303:337-45.

34. Kim CNH, Hutcheon J, van Schalkwyk J, Routsi E, Farmaki M, Vlahos N, et al. Maternal outcome of pregnant women admitted to intensive care units for coronavirus disease 2019. Am J Obstet Gynecol 2020;223:773-4.

35. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on maternal and neonatal outcomes: A systematic review and meta-analysis. Clin Microbiol Infect 2021;27:36-46.

36. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ 2020;370:m3320.

37. Khalil A, Kalafat E, Benlioglu C, O’Brien P, Morris E, Draycott T, et al. SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine 2020;25:100446. doi: 10.1016/j.eclinm.2020.100446.

38. WAPM (World Association of Perinatal Medicine) Working Group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection. Ultrasound Obstet Gynecol 2021;57:232-41.

39. Takemoto M, Menezes MO, Andreucci CB, Knobel R, Sousa L, Katz L, et al. Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: A surveillance database analysis. BJOG 2020;127:1618-26.

40. Antoun L, Taweel NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study. Eur J Obstet Gynecol Reprod Biol 2020;252:559-62.

41. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: Systematic review. Ultrasound Obstet Gynecol 2020;56:15-27.

42. Operational Guidance for COVID19 vaccination of Pregnant Woman.pdf. Available from: https://www.mohfw.gov.in/pdf/OperationalGuidance for COVID19 vaccination of Pregnant Woman.pdf. [Last accessed on 2021 Jul 13].